Establishment of a new murine model of hypercalcemia with anorexia by overexpression of soluble receptor activator of NF-κB ligand using an adenovirus vector

[1]  A. Haeseler,et al.  Central control of fever and female body temperature by RANKL/RANK , 2009, Nature.

[2]  N. Udagawa,et al.  Evaluation of Pharmaceuticals With a Novel 50‐Hour Animal Model of Bone Loss , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  P. Kostenuik,et al.  Soluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice , 2008, Calcified Tissue International.

[4]  T. Kodama,et al.  Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals , 2008, Cell.

[5]  A. Roma,et al.  Medical treatment of malignancy-associated hypercalcemia. , 2008, Current medicinal chemistry.

[6]  P. Kostenuik,et al.  Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease , 2008, Osteoporosis International.

[7]  E. Ogata,et al.  Parathyroid hormone–related protein (PTHrP) as a causative factor of cancer‐associated wasting: Possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts , 2005, International journal of cancer.

[8]  X. Mariette,et al.  The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression , 2004, Leukemia & lymphoma.

[9]  E. Ogata,et al.  Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. , 2003, Seminars in oncology.

[10]  Felix Eckstein,et al.  Precision and Accuracy of Peripheral Quantitative Computed Tomography (pQCT) in the Mouse Skeleton Compared With Histology and Microcomputed Tomography (μCT) , 2003 .

[11]  F. Eckstein,et al.  Precision and accuracy of peripheral quantitative computed tomography (pQCT) in the mouse skeleton compared with histology and microcomputed tomography (microCT). , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  M. Pecherstorfer,et al.  Current Management Strategies for Hypercalcemia , 2003, Treatments in endocrinology.

[13]  H. Yasuda,et al.  Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis , 2002, Journal of Bone and Mineral Metabolism.

[14]  P. Kostenuik,et al.  Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. , 2000, Cancer research.

[15]  S. Morony,et al.  A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL‐1β, TNF‐α, PTH, PTHrP, and 1,25(OH)2D3 , 1999 .

[16]  F. Tashiro,et al.  Constructing adenoviral vectors by using the circular form of the adenoviral genome cloned in a cosmid and the Cre-loxP recombination system. , 1999, Human gene therapy.

[17]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Morony,et al.  A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  T. Martin,et al.  Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .

[20]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.

[21]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[22]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Shirahata,et al.  Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats. , 1998, Japanese journal of pharmacology.

[24]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[25]  G. Strassmann,et al.  Mechanisms of paraneoplastic syndromes of colon-26: involvement of interleukin 6 in hypercalcemia. , 1993, Cytokine.

[26]  G. Strassmann,et al.  Evidence for the involvement of interleukin 6 in experimental cancer cachexia. , 1992, The Journal of clinical investigation.

[27]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[28]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.

[29]  T. Martin,et al.  Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. , 1991, The Journal of clinical endocrinology and metabolism.

[30]  L. Suva,et al.  PARATHYROID HORMONE‐RELATED PROTEIN IN HYPERCALCAEMIA OF MALIGNANCY , 1989, Clinical endocrinology.

[31]  J. Bonjour,et al.  Role of bone and kidney in parathyroid hormone‐related peptide‐induced hypercalcemia in rats , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.